Bristol Myers Squibb (CELG-RI) EBT (2009 - 2026)

Bristol Myers Squibb has disclosed EBT across 18 years of filings, most recently posting $3.2 billion for Q1 2026.

• In Q1 2026, EBT rose 9.05% year-over-year to $3.2 billion; the TTM figure through Mar 2026 stood at $9.6 billion (up 57.12% YoY), while the FY2025 annual figure was $9.3 billion, up 211.33% from the prior year.
• EBT advanced to $3.2 billion in Q1 2026, from $1.5 billion in the prior quarter.
• Over the last five years, EBT for CELG-RI reached as high as $3.2 billion in Q1 2026 and fell as low as -$11.5 billion in Q1 2024.
• The 5-year median for EBT is $1.9 billion (2022), against an average of $1.2 billion.
• Annual changes were most pronounced in 2024 — EBT slumped 515.74% — and 2025, when it surged 740.0%.
• A 5-year view of EBT shows it stood at $1.9 billion in 2022, then retreated by 9.95% to $1.7 billion in 2023, then tumbled by 89.55% to $175.0 million in 2024, then surged by 740.0% to $1.5 billion in 2025, then jumped by 120.41% to $3.2 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $3.2 billion, $1.5 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.